Simple Summary According to the American Cancer Society, approximately 53,000 new
cases of thyroid cancer were diagnosed and more than 2200 people died from the disease …

Simple Summary Medullary thyroid carcinoma (MTC) is a rare neoplasm that is responsible
for a fair proportion of thyroid carcinoma related deaths. The current diagnostic and …

The treatment options that are currently available for management of metastatic, progressive
radioactive iodine (RAI)-refractory differentiated thyroid cancers (DTCs), and medullary …

Medullary thyroid carcinoma (MTC) is a rare malignancy comprising 1–2% of all thyroid
cancers in the United States. Approximately 20% of cases are familial, secondary to a …

Effective treatment options in advanced/progressive/metastatic medullary thyroid carcinoma
(MTC) are currently limited. As in other neuroendocrine neoplasms (NENs), peptide receptor …

G-protein-coupled receptors (GPCRs) are increasingly being considered as possible
therapeutic targets in cancers. Activation of GPCR on tumors can have prominent growth …

Introduction Medullary thyroid carcinoma (MTC) is a rare thyroid malignancy originating from
parafollicular C cells. It accounts for 5%–10% of all thyroid malignancies. Methods An …

Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC), though uncommon,
presents a considerable therapeutic challenge with poor long-term outcomes. Currently …

In the last two decades, science has largely evolved in methodologies for cancer treatment,
yet, the basic backbone of cancer treatment includes surgery, chemotherapy and radiation …

Molecular imaging is pivotal in evaluating and managing patients with different thyroid
cancer histotypes. The existing, pathology-based, risk stratification systems can be usefully …